Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794544 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT03794544 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 84 participants.
The verdict
NCT03794544, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I \[\>2cm\] to IIIA) non-small cell lung cancer (NSCLC).
Interventions
- DRUG Durvalumab
- COMBINATION_PRODUCT Oleclumab
- COMBINATION_PRODUCT Monalizumab
- COMBINATION_PRODUCT Danvatirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2021-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03794544
The ClinicalTrials.gov registry entry for NCT03794544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Durvalumab is the first listed.
NCT03794544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03794544 about?
NCT03794544 is a clinical study titled "Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer". Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I \[\>2cm\] to IIIA) non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03794544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2019-03-08. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT03794544?
The interventions under investigation include: Durvalumab (DRUG), Oleclumab (COMBINATION_PRODUCT), Monalizumab (COMBINATION_PRODUCT), Danvatirsen (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03794544?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.